复星医药：丁二酸复瑞替尼胶囊药品注册申请获受理

Core Viewpoint - Fosun Pharma has submitted a drug registration application for SAF-189, a drug for treating ALK-positive locally advanced or metastatic non-small cell lung cancer, which has been accepted by the National Medical Products Administration [1] Group 1 - Fosun Pharma's subsidiary, Fosun Wanguo (Jiangsu) Pharmaceutical Group Co., Ltd., is responsible for the drug registration application [1] - The application is classified as a Class 1 chemical drug [1] - The indication for the drug is specifically for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer [1]